Natural Killer Cell Activity

Your immune system has a first-response team that hunts down infected or transformed cells before your body even mounts a full defense. Natural killer (NK) cells lead that team, and how well they actually kill targets is something a standard CBC (complete blood count) cannot tell you. A test that measures NK cell activity captures function, not just how many cells are circulating.

This matters because low NK activity has been linked to higher odds of colorectal and prostate cancer at diagnosis, worse outcomes in several solid tumors, and a host of inflammatory and metabolic conditions. The number on this report reflects how aggressively your innate immune system can respond when it encounters trouble.

What This Test Actually Measures

NKA (natural killer cell activity) tests typically stimulate your blood sample in a tube and measure how much interferon-gamma (a signaling protein NK cells release when activated) the cells produce, or how well they destroy lab-grown target cells. A high reading means your NK cells respond vigorously when challenged. A low reading means they respond weakly, regardless of how many NK cells you have.

This is different from a CBC, which counts cells but says nothing about whether those cells work. Two people with identical lymphocyte counts can have very different NK function. The activity test is the part standard labs miss.

Cancer Risk and Prognosis

The strongest human evidence ties low NK activity to cancer. In 872 adults referred for colonoscopy, those with colorectal cancer had a median NK activity of 86.0 pg/mL versus 298.1 pg/mL in those without cancer. Using a research cutoff, the test caught about 87 out of 100 cancer cases (87% sensitivity) and correctly cleared about 61 out of 100 cancer-free people (60.8% specificity), with a negative predictive value of 99.4%. People in the low-activity group had roughly 10 times the odds of having colorectal cancer.

In 94 men referred for prostate biopsy, those in the low NK activity group had about 5 times the odds of having prostate cancer (odds ratio 4.89). It is worth keeping in mind that in this study the NK activity test only caught about 34 out of 100 prostate cancers (34% sensitivity, 88% specificity), so it missed roughly two-thirds of cases and should not be used as a standalone screening tool. In pancreatic cancer, low NK activity tracked with worse response to chemotherapy, faster progression, and shorter survival. In breast cancer, the 5-year invasive disease-free survival was 88.1% for patients with normal NK activity before surgery versus 71.5% for those with low activity. Across solid tumors, tumor-infiltrating NK cells consistently predict longer overall survival.

Hyper-Inflammatory Syndromes

For adults with unexplained fever and dropping blood counts, NK testing is sometimes used as part of the workup for hemophagocytic lymphohistiocytosis (HLH), a runaway inflammatory syndrome. In one single-center study, flow-based NK cytotoxicity testing caught about 96 out of 100 HLH cases, and an interferon-gamma–based NK activity test caught about 92 out of 100. Combining low NK activity with very high ferritin (a marker of extreme inflammation) correctly cleared HLH in about 94 out of 100 non-HLH patients in that same study.

Performance varies widely across populations and assays. A larger study found classic NK cytotoxicity testing had only about 59.5% sensitivity for detecting biallelic HLH mutations, with perforin and CD107a (degranulation) testing performing better. The North American Consortium for Histiocytosis recommends degranulation assays over NK cell function testing for HLH screening, and the updated HLH-2024 diagnostic criteria have removed NK cell activity as a standalone criterion. NK activity testing can add information in an HLH workup, but it should be interpreted alongside perforin, CD107a, and genetic testing rather than relied on alone.

Metabolic and Autoimmune Disease

NK activity is markedly reduced in type 2 diabetes and tracks inversely with blood-sugar control, suggesting chronic metabolic stress dulls innate immunity. In childhood-onset lupus, absolute NK cell count independently predicted disease activity, lupus nephritis, and time to first remission. In systemic sclerosis, NK counts dropped further when pulmonary arterial hypertension developed. In myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), impaired NK cytotoxicity was the single most consistent immune finding across studies.

Severe Viral Infection

In severe COVID-19, NK cell counts and cytotoxic function were both significantly reduced compared with milder disease, and the impairment tracked with elevated inflammatory signaling. The same pattern appears in other serious viral and bacterial infections, where weak NK responses correlate with worse outcomes.

Why Tracking Beats a Single Reading

NK activity varies widely between healthy people in research populations and shifts with age, sex, neutrophil-to-lymphocyte ratio, and current inflammation. A single number is hard to interpret in isolation. Tracking your trend across multiple draws in a stable health state is far more useful than chasing one value. No established clinical guideline currently endorses routine serial NK activity monitoring in asymptomatic people, so use serial testing as a personal tracking tool rather than a screening protocol.

Get a baseline, then retest in 3 to 6 months if you are making meaningful changes (weight loss, treating an infection, starting a new medication). Repeat at least annually after that. A repeat measurement under similar conditions is the only way to tell whether a low reading reflects your true baseline or a temporary dip.

When Results Can Be Misleading

• Acute illness or recent infection: severe viral or bacterial infection can suppress NK function for weeks. In severe COVID-19, mature cytotoxic NK frequency and killing capacity were both reduced. Wait until you have been well for at least a few weeks before testing.
• Recent surgery, anesthesia, or strong opioids: in colorectal cancer surgery cohorts, NK cytotoxicity dropped significantly at 1, 24, and 48 hours after operation. Fentanyl, morphine, oxycodone, sevoflurane, and ketamine have been associated with lower NK activity in the perioperative window. Propofol is often grouped with these agents, but the evidence is mixed: at least one randomized trial in colorectal cancer surgery found no significant difference between propofol and sevoflurane on NK cell fractions, and some in vitro data suggest propofol may be less suppressive than volatile anesthetics.
• Corticosteroids and certain prescription drugs: prednisolone has been shown to impair NK activity measurement in breast cancer patients. Sulfasalazine significantly suppressed NK activity in most treated subjects (about two-thirds in the original study) after 4 weeks, with recovery after stopping. Daratumumab (an anti-CD38 cancer drug) rapidly reduces circulating NK counts during treatment.
• High neutrophil-to-lymphocyte ratio: in healthy adults, a higher neutrophil-to-lymphocyte ratio (a sign of acute inflammation) was associated with lower interferon-gamma–based NK activity, independent of true NK function.

Decision Pathway for Unexpected Results

A low NK activity result is a signal to investigate, not to panic. The first step is to repeat the test in a stable health state, off recent steroids or opioids, and away from acute infection. If the low reading persists, look at the rest of your picture: ferritin (to flag hyperinflammation), CBC with differential, hs-CRP (high-sensitivity C-reactive protein, a sensitive inflammation marker), HbA1c (a 3-month average of blood sugar), and age- and sex-appropriate cancer screening including colonoscopy. These steps reflect expert clinical reasoning rather than a formal guideline.

A persistently low NK activity combined with very high ferritin warrants urgent evaluation for HLH by a hematologist, ideally with degranulation (CD107a) and perforin testing rather than NK activity alone. Combined with elevated PSA (prostate-specific antigen), a low NK result can support pursuing a urology workup, but because the NK activity test missed about two-thirds of prostate cancers in the published study, a normal NK result should not be used to defer a workup that PSA or symptoms otherwise justify. In adults with risk factors for colorectal cancer, low NK activity is a reason to push forward with colonoscopy rather than defer it. Pair the result with the workup that matches your other risks, rather than treating the number as a standalone verdict.

How This Differs From an NK Cell Count

A standard immune panel may report NK cell numbers as part of a lymphocyte subset analysis (CD16+CD56+ cells per microliter). That tells you how many NK cells are present. The activity test tells you how well they function. Both are useful, but only the activity test captures the kind of dysfunction seen in cancer, autoimmune disease, and severe viral infection, where cells are present but underperform.